Viatris, the drugmaker formerly known as Mylan, agreed to pay $264 million to resolve a class action lawsuit alleging the company engaged in a scheme to delay generic competition to its EpiPen allergy treatment.
The three largest U.S. drug distributors and drugmaker Johnson & Johnson agreed to finalize a proposed $26 billion settlement resolving claims by states and local governments that they helped fuel the U.S. opioid epidemic.
Martin Shkreli received his second lifetime ban from the pharmaceutical industry. One month after U.S. District Court Judge Denise Cotes banned the “Pharma Bro” from future involvement in the industry, a second judge handed down a similar order and ordered him to pay a $1.39 million fine.
A Johnson & Johnson subsidiary proposed on February 18 that it would submit to an independent examination of the corporate restructuring the healthcare giant undertook in an attempt to settle in U.S. bankruptcy court thousands of lawsuits alleging that J&J baby powder and other talc products cause cancer.
A federal judge on February 16 dismissed a proposed class action lawsuit by consumers who accused Pfizer Inc. of failing to disclose the presence of cancer-causing agents in Chantix before recalling the anti-smoking drug.
A Johnson & Johnson subsidiary came under attack in court on February 14 for attempting to use the bankruptcy process to resolve tens of thousands of claims that J&J’s baby powder and other talc-based products caused cancer.
New York Governor Kathy Hochul is ending her state’s mask mandate for most indoor public places, The New York Times reported, joining several states due to lift face-covering rules as the latest COVID-19 surge eases.
Johnson & Johnson accused attorneys for people who have sued the pharmaceutical giant over the company’s talc products of sharing confidential documents with Reuters in what J&J called a “calculated effort” to try its subsidiary’s bankruptcy case in the press.
Britain’s GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between GSK’s HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.
The three largest U.S. drug distributors and drugmaker Johnson & Johnson agreed to pay $590 million to resolve claims by Native American tribes that the companies fueled an opioid epidemic in their communities, according to court filings.
